This statistic describes the global pharmaceutical sales in from 2020 to 2024, sorted by regional submarkets. For 2024, total pharmaceutical sales in the United States was estimated to reach around *** billion U.S. dollars. World pharmaceutical sales by regionThe pharmaceutical industry is best known for manufacturing pharmaceutical drugs which aim to diagnose, cure, treat, or prevent diseases. The pharmaceutical sector represents a huge industry, with the global market being worth around *** trillion U.S. dollars. Among the best known top global pharmaceutical companies are Pfizer, Merck and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Accordingly, North America and Europe are still among the largest global submarkets for pharmaceuticals. In 2024, the United States was still the largest single pharmaceutical market, generating more than *** billion U.S. dollars of revenue. Europe was responsible for generating around *** billion U.S. dollars. These two markets, together with Japan, Canada and Australia, form the so-called established (or developed) markets. The rest of the global pharmaceutical revenue is mainly from emerging markets, which include countries like China, Russia, Brazil and India. In fact, these emerging markets show the fastest increase in pharmaceutical sales. Latin America is the world region with the highest predicted compound annual growth rate until 2028.

The global pharmaceutical market has experienced significant growth in recent years. For 2024, the total global pharmaceutical market was estimated at around *** trillion U.S. dollars. This is an increase of roughly *** billion dollars compared to 2023. Global pharmaceutical markets Globally, the United States is by far the leading market for pharmaceuticals, followed by other developed countries and emerging markets. Emerging markets can include middle and low-income countries such as Brazil, India, Russia, Colombia and Egypt, to name a few. Despite increasing revenues globally, the Latin American region accounts for the lowest share of the global pharmaceutical market’s revenues. Top pharmaceuticals globally The top pharmaceutical products sold globally include Humira, Eliquis and Revlimid. Oncology is the op therapeutic area for drug sales globally, and it is expected to show the largest growth over the next years. It is followed by drug spending for autoimmune diseases and diabetes. During the height of the COVID-19 pandemic, Comirnaty was the world's top revenue generating pharmaceutical product.

Graph and download economic data for Employment for Manufacturing: Pharmaceutical and Medicine Manufacturing (NAICS 32541) in the United States (IPUEN32541W201000000) from 1988 to 2024 about medicines, pharmaceuticals, NAICS, IP, manufacturing, employment, and USA.

Graph and download economic data for Unit Labor Costs for Manufacturing: Pharmaceutical and Medicine Manufacturing (NAICS 3254) in the United States (IPUEN3254U100000000) from 1987 to 2024 about medicines, pharmaceuticals, unit labor cost, NAICS, IP, manufacturing, and USA.

Pharmaceuticals Market size was valued at USD 1,550.84 Billion in 2023 and is poised to grow from USD 1,645.75 Billion in 2024 to USD 2,646.93 Billion by 2032, growing at a CAGR of 6.12% in the forecast period (2025-2032).

Success.ai’s Pharma Data for the Global Pharmaceutical Industry provides a robust dataset tailored for businesses looking to connect with pharmaceutical companies, decision-makers, and key stakeholders worldwide. Covering pharmaceutical manufacturers, research organizations, biotech firms, and distributors, this dataset offers verified SIC codes, firmographic details, and contact information for executives and operational leads.

With access to over 170 million verified professional profiles and 30 million company profiles, Success.ai ensures your outreach, market research, and business development strategies are driven by reliable, continuously updated, and AI-validated data. Supported by our Best Price Guarantee, this solution is essential for navigating the competitive global pharmaceutical landscape.

Why Choose Success.ai’s Pharma Data?

1. Verified Contact Data for Precision Outreach

   • Access verified work emails, phone numbers, and LinkedIn profiles of pharmaceutical executives, R&D leads, compliance officers, and procurement managers.
   • AI-driven validation ensures 99% accuracy, optimizing your campaigns and improving communication efficiency.

2. Comprehensive Coverage of the Global Pharmaceutical Sector

   • Includes profiles of pharmaceutical companies, biotech firms, contract manufacturing organizations (CMOs), and distributors across North America, Europe, Asia, and other major markets.
   • Gain insights into regional pharmaceutical trends, product pipelines, and market dynamics unique to global markets.

3. Continuously Updated Datasets

   • Real-time updates reflect leadership changes, mergers, product launches, and regulatory compliance shifts.
   • Stay aligned with the fast-paced pharmaceutical industry to capitalize on emerging opportunities and maintain relevance.

4. Ethical and Compliant

   • Adheres to GDPR, CCPA, and other global privacy regulations, ensuring responsible use of data and compliance with legal standards.

Data Highlights:

• 170M+ Verified Professional Profiles: Engage with decision-makers, R&D specialists, and operational leaders in the pharmaceutical industry worldwide.
• 30M Company Profiles: Access detailed firmographic data, including company sizes, revenue ranges, and geographic footprints.
• Verified SIC Codes: Understand industry classifications and product specializations to refine your targeting strategies.
• Leadership Contact Details: Connect with CEOs, COOs, medical directors, and regulatory managers influencing pharmaceutical operations.

Key Features of the Dataset:

1. Decision-Maker Profiles in Pharmaceuticals

   • Identify and engage with professionals overseeing R&D, clinical trials, supply chains, and regulatory compliance.
   • Target leaders responsible for drug development, vendor selection, and market entry strategies.

2. Advanced Filters for Precision Targeting

   • Filter companies by industry segment (biotech, generic pharmaceuticals, vaccines), geographic location, or revenue size.
   • Tailor campaigns to align with specific needs such as drug pipeline acceleration, production scaling, or market expansion.

3. SIC Codes and Firmographic Insights

   • Access verified SIC codes and detailed company profiles to understand market focus, operational scale, and specialization areas.
   • Use firmographic data to prioritize high-value targets and align product offerings with market demands.

4. AI-Driven Enrichment

   • Profiles enriched with actionable data allow for personalized messaging, highlight unique value propositions, and improve engagement outcomes with pharmaceutical stakeholders.

Strategic Use Cases:

1. Sales and Lead Generation

   • Offer technology solutions, research tools, or contract services to pharmaceutical manufacturers, R&D facilities, and distribution networks.
   • Build relationships with procurement teams and compliance officers responsible for vendor approvals and operational excellence.

2. Market Research and Product Development

   • Analyze global pharmaceutical trends, drug approval patterns, and regulatory frameworks to guide product innovation and market entry strategies.
   • Identify high-growth regions and emerging therapeutic areas to focus your resources effectively.

3. Partnership and Supply Chain Development

   • Connect with pharmaceutical companies seeking contract manufacturing, raw material sourcing, or distribution partnerships.
   • Foster alliances that streamline production, ensure quality, and accelerate time-to-market.

4. Regulatory Compliance and Risk Mitigation

   • Engage with regulatory officers and compliance managers overseeing adherence to local and international pharmaceutical standards.
   • Present solutions for documentation, reporting, and risk management to ensure compliance and operational efficiency.

Why Choose Success.ai?

1. Best Price Guarantee
   ...

Key information about United States Imports: Medicinal and Pharmaceutical Product

• United States Imports: Medicinal and Pharmaceutical Product was reported at 90,202,040.529 USD th in Dec 2023
• This records an increase from the previous number of 73,244,161.749 USD th for Dec 2022
• US Imports: Medicinal and Pharmaceutical Product data is updated yearly, averaging 14,847,092.578 USD th from Dec 1995 to 2023, with 29 observations
• The data reached an all-time high of 90,202,040.529 USD th in 2023 and a record low of 2,774,555.392 USD th in 1995
• US Imports: Medicinal and Pharmaceutical Product data remains active status in CEIC and is reported by United Nations Conference on Trade and Development
• The data is categorized under World Trend Plus’s Association: Pharmaceutical and Biotechnology Sector – Table RT.UNCTAD.MPP: Medicinal and Pharmaceutical Product: Imports Value by Individual Economies and Territories

The leading pharmaceutical company worldwide in 2023 was Johnson & Johnson, however, also including non-pharmaceutical sales. A global view on the industryThe total global pharmaceutical market was worth around *** trillion U.S. dollars in 2023. North America remains the strongest regional market worldwide, responsible for nearly half of the global market size. The largest national pharmaceutical market is the United States, making up almost half of global medicine spending. Thus, * of the ** largest pharmaceutical companies worldwide were from the United States in 2023. One reason for this is that the U.S. is still the world’s largest hub for life sciences and medical research and knowledge. The importance of innovationPharmaceutical companies are to a considerable part – more than in most other industries – driven by the imperative to produce innovative products and to invest in research and development. Once a new drug, for example, is launched, the clock is already ticking towards the loss of patent protection. In particular, companies that depend on a small number of blockbuster drugs, are under threat of heavy revenue loss. Two effects of patent expirations for the pharma industry are high R&D concentration and a growing focus on specialty drugs.

Pharmaceutical Industry Software Market Outlook

The global pharmaceutical industry software market size was valued at approximately USD 4.5 billion in 2023 and is expected to reach USD 8.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period. This growth is driven by an increasing demand for efficient data management solutions, technological advancements, and regulatory compliance requirements within the pharmaceutical sector. The market is propelled by the need for enhanced operational efficiency and data-driven decision-making, which are critical in the highly competitive pharmaceutical landscape. Additionally, the ongoing digital transformation within the industry and the adoption of advanced technologies such as AI, machine learning, and blockchain are expected to further fuel the market's growth.

One of the major growth factors contributing to the expansion of the pharmaceutical industry software market is the increasing complexity and volume of data generated in pharmaceutical operations. As companies strive to accelerate drug discovery and development while ensuring compliance with stringent regulatory standards, the need for robust software solutions to manage, analyze, and interpret vast amounts of data becomes paramount. Laboratory Information Management Systems (LIMS) and Regulatory Compliance Software have become essential tools, providing comprehensive data management capabilities and ensuring adherence to regulations such as FDA and EMA guidelines. Moreover, the growing trend of personalized medicine and the increasing focus on real-world data and evidence have further underscored the importance of efficient data management solutions in the pharmaceutical sector.

Technological advancements and innovations in pharmaceutical industry software are also key drivers of market growth. The integration of artificial intelligence, machine learning, and other advanced analytics capabilities into software solutions has transformed the pharmaceutical landscape. These technologies enable companies to improve data accuracy, optimize clinical trials, and streamline regulatory submissions. Furthermore, the adoption of cloud-based solutions has gained significant traction, offering scalability, flexibility, and cost-effectiveness to pharmaceutical companies. Cloud-based software solutions facilitate seamless data sharing across global teams, enhance collaboration, and reduce the need for extensive IT infrastructure, making them an attractive option for companies of all sizes.

The rise of precision medicine and the increasing importance of patient-centric approaches have further fueled the demand for pharmaceutical industry software. As companies aim to deliver targeted therapies and improve patient outcomes, software solutions that support these initiatives are gaining prominence. Clinical Trial Management Systems (CTMS) and Quality Management Systems (QMS) play a crucial role in optimizing clinical trial operations, ensuring data integrity, and maintaining product quality throughout the lifecycle. Additionally, the growing emphasis on pharmacovigilance and risk management has led to the adoption of specialized software solutions that enable companies to monitor and mitigate potential risks associated with their products.

From a regional perspective, North America is expected to dominate the pharmaceutical industry software market during the forecast period, owing to the presence of a well-established pharmaceutical industry, advanced healthcare infrastructure, and favorable government initiatives supporting digital transformation. Europe is also anticipated to witness significant growth, driven by stringent regulatory requirements and increasing investments in research and development activities. Meanwhile, the Asia Pacific region is projected to experience the highest growth rate, attributed to the rapidly expanding pharmaceutical sector, growing healthcare expenditure, and increasing adoption of digital technologies in emerging economies such as China and India.

Software Type Analysis

The software type segment of the pharmaceutical industry software market encompasses a diverse array of solutions tailored to address specific requirements within the industry. Laboratory Information Management Systems (LIMS) stand out as a vital component, offering functionalities that streamline laboratory workflows, automate data collection, and enhance data integrity. By facilitating efficient sample management and enabling real-time data analysis, LIMS play a critical role in accelerating drug discovery and development processes. The market for LIMS is buoyed by the gr

Through the Medicines and Resources Information Project (GIP), the National Health Care Institute has an independent, reliable and representative information system that contains data on the use of medicines and resources in the Netherlands. The Zorginstituut uses this data to map the developments in the use of medicines and aids and the associated costs.

Since 2004, the data files of the GIP have been made accessible via www.gipdatabank.nl . The GIP database is a unique public data source with detailed figures on the use of medicines and aids in the Netherlands over the past five years. Here you will find detailed information about the volume (number of dispensations and number of standard daily doses), the associated costs and the number of users of medicines and aids.

The data files of the GIP are based on the claim data for pharmaceutical care (including diet and food) and medical aids, from 19 health insurers (risk-bearing labels). This concerns medicines and medical aids that have been prescribed extramurally by the general practitioner or the specialist, and subsequently dispensed by a pharmacist, dispensing general practitioner or supplier of medical aids. This concerns medicines and medical aids that are reimbursed by the health insurer on the basis of the Health Insurance Act (basic insurance).

[240+ Pages Report] The global Pharmaceutical market size is expected to grow from USD 1,482.4 million to USD 2,067.36 million by 2028, at a CAGR of 5.70% from 2022-2028

Update — December 7, 2014. – Evidence-based medicine (EBM) is not working for many reasons, for example: 1. Incorrect in their foundations (paradox): hierarchical levels of evidence are supported by opinions (i.e., lowest strength of evidence according to EBM) instead of real data collected from different types of study designs (i.e., evidence). http://dx.doi.org/10.6084/m9.figshare.1122534 2. The effect of criminal practices by pharmaceutical companies is only possible because of the complicity of others: healthcare systems, professional associations, governmental and academic institutions. Pharmaceutical companies also corrupt at the personal level, politicians and political parties are on their payroll, medical professionals seduced by different types of gifts in exchange of prescriptions (i.e., bribery) which very likely results in patients not receiving the proper treatment for their disease, many times there is no such thing: healthy persons not needing pharmacological treatments of any kind are constantly misdiagnosed and treated with unnecessary drugs. Some medical professionals are converted in K.O.L. which is only a puppet appearing on stage to spread lies to their peers, a person supposedly trained to improve the well-being of others, now deceits on behalf of pharmaceutical companies. Probably the saddest thing is that many honest doctors are being misled by these lies created by the rules of pharmaceutical marketing instead of scientific, medical, and ethical principles. Interpretation of EBM in this context was not anticipated by their creators. “The main reason we take so many drugs is that drug companies don’t sell drugs, they sell lies about drugs.” ―Peter C. Gøtzsche “doctors and their organisations should recognise that it is unethical to receive money that has been earned in part through crimes that have harmed those people whose interests doctors are expected to take care of. Many crimes would be impossible to carry out if doctors weren’t willing to participate in them.” —Peter C Gøtzsche, The BMJ, 2012, Big pharma often commits corporate crime, and this must be stopped. Pending (Colombia): Health Promoter Entities (In Spanish: EPS ―Empresas Promotoras de Salud).

1. Misinterpretations New technologies or concepts are difficult to understand in the beginning, it doesn’t matter their simplicity, we need to get used to new tools aimed to improve our professional practice. Probably the best explanation is here in these videos (credits to Antonio Villafaina for sharing these videos with me). English https://www.youtube.com/watch?v=pQHX-SjgQvQ&w=420&h=315 Spanish https://www.youtube.com/watch?v=DApozQBrlhU&w=420&h=315 ----------------------- Hypothesis: hierarchical levels of evidence based medicine are wrong Dear Editor, I have data to support the hypothesis described in the title of this letter. Before rejecting the null hypothesis I would like to ask the following open question:Could you support with data that hierarchical levels of evidence based medicine are correct? (1,2) Additional explanation to this question: – Only respond to this question attaching publicly available raw data.– Be aware that more than a question this is a challenge: I have data (i.e., evidence) which is contrary to classic (i.e., McMaster) or current (i.e., Oxford) hierarchical levels of evidence based medicine. An important part of this data (but not all) is publicly available. References
2. Ramirez, Jorge H (2014): The EBM challenge. figshare. http://dx.doi.org/10.6084/m9.figshare.1135873
3. The EBM Challenge Day 1: No Answers. Competing interests: I endorse the principles of open data in human biomedical research Read this letter on The BMJ – August 13, 2014.http://www.bmj.com/content/348/bmj.g3725/rr/762595Re: Greenhalgh T, et al. Evidence based medicine: a movement in crisis? BMJ 2014; 348: g3725. _ Fileset contents Raw data: Excel archive: Raw data, interactive figures, and PubMed search terms. Google Spreadsheet is also available (URL below the article description). Figure 1. Unadjusted (Fig 1A) and adjusted (Fig 1B) PubMed publication trends (01/01/1992 to 30/06/2014). Figure 2. Adjusted PubMed publication trends (07/01/2008 to 29/06/2014) Figure 3. Google search trends: Jan 2004 to Jun 2014 / 1-week periods. Figure 4. PubMed publication trends (1962-2013) systematic reviews and meta-analysis, clinical trials, and observational studies.
   Figure 5. Ramirez, Jorge H (2014): Infographics: Unpublished US phase 3 clinical trials (2002-2014) completed before Jan 2011 = 50.8%. figshare.http://dx.doi.org/10.6084/m9.figshare.1121675 Raw data: "13377 studies found for: Completed | Interventional Studies | Phase 3 | received from 01/01/2002 to 01/01/2014 | Worldwide". This database complies with the terms and conditions of ClinicalTrials.gov: http://clinicaltrials.gov/ct2/about-site/terms-conditions Supplementary Figures (S1-S6). PubMed publication delay in the indexation processes does not explain the descending trends in the scientific output of evidence-based medicine. Acknowledgments I would like to acknowledge the following persons for providing valuable concepts in data visualization and infographics:
4. Maria Fernanda Ramírez. Professor of graphic design. Universidad del Valle. Cali, Colombia.
5. Lorena Franco. Graphic design student. Universidad del Valle. Cali, Colombia. Related articles by this author (Jorge H. Ramírez)
6. Ramirez JH. Lack of transparency in clinical trials: a call for action. Colomb Med (Cali) 2013;44(4):243-6. URL: http://www.ncbi.nlm.nih.gov/pubmed/24892242
7. Ramirez JH. Re: Evidence based medicine is broken (17 June 2014). http://www.bmj.com/node/759181
8. Ramirez JH. Re: Global rules for global health: why we need an independent, impartial WHO (19 June 2014). http://www.bmj.com/node/759151
9. Ramirez JH. PubMed publication trends (1992 to 2014): evidence based medicine and clinical practice guidelines (04 July 2014). http://www.bmj.com/content/348/bmj.g3725/rr/759895 Recommended articles
10. Greenhalgh Trisha, Howick Jeremy,Maskrey Neal. Evidence based medicine: a movement in crisis? BMJ 2014;348:g3725
11. Spence Des. Evidence based medicine is broken BMJ 2014; 348:g22
12. Schünemann Holger J, Oxman Andrew D,Brozek Jan, Glasziou Paul, JaeschkeRoman, Vist Gunn E et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies BMJ 2008; 336:1106
13. Lau Joseph, Ioannidis John P A, TerrinNorma, Schmid Christopher H, OlkinIngram. The case of the misleading funnel plot BMJ 2006; 333:597
14. Moynihan R, Henry D, Moons KGM (2014) Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much. PLoS Med 11(7): e1001655. doi:10.1371/journal.pmed.1001655
15. Katz D. A-holistic view of evidence based medicinehttp://thehealthcareblog.com/blog/2014/05/02/a-holistic-view-of-evidence-based-medicine/ ---

West is a trusted partner to the world's top pharmaceutical and biotechnology companies, working together to improve patient health. Their company background emphasizes the importance of their designs and products, which nurture a culture of philanthropy and community involvement.

The company provides various solutions, including vial containment, prefilled syringe components, self-injection technologies, cartridge systems, and quality enhancements. These solutions promote the efficiency, reliability, and safety of the world's pharmaceutical drug supply.

West also emphasizes the importance of culture, stating that nurturing a culture of philanthropy and community involvement is one of the defining characteristicsn

Costa Rica Pharmaceutical Industry: Total Imports data was reported at 902.888 USD mn in 2021. This records an increase from the previous number of 844.139 USD mn for 2020. Costa Rica Pharmaceutical Industry: Total Imports data is updated yearly, averaging 429.064 USD mn from Dec 1994 (Median) to 2021, with 28 observations. The data reached an all-time high of 902.888 USD mn in 2021 and a record low of 97.296 USD mn in 1994. Costa Rica Pharmaceutical Industry: Total Imports data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Costa Rica – Table CR.OECD.MSTI: Trade Statistics: OECD Member: Annual.

MSTI indicators on GBARD do not currently cover Costa Rica. Therefore, OECD totals include Costa Rica for all indicators except those on GBARD.

Graph and download economic data for All Employees: Manufacturing: Non-Durable Goods: Pharmaceutical and Medicine Manufacturing in New York (SMU36000003232540001SA) from Jan 1990 to May 2025 about medicines, pharmaceuticals, nondurable goods, NY, goods, manufacturing, employment, and USA.

Graph and download economic data for Real Sectoral Output for Manufacturing: Pharmaceutical and Medicine Manufacturing (NAICS 3254) in the United States (IPUEN3254T010000000) from 1987 to 2024 about medicines, pharmaceuticals, output, NAICS, IP, manufacturing, and USA.

Number of Businesses statistics on the Brand Name Pharmaceutical Manufacturing industry in United States

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical and Medicine Manufacturing (PCU3254132541) from Dec 2003 to May 2025 about medicines, pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

Graph and download economic data for Capital Costs for Manufacturing: Pharmaceutical and Medicine Manufacturing (NAICS 3254) in the United States (IPUEN3254C020000000) from 1987 to 2021 about medicines, pharmaceuticals, cost, NAICS, capital, IP, manufacturing, and USA.

In the pharmaceutical industry, the shelf-life of a drug product is determined by data gathered from stability studies and is intended to provide consumers with a high degree of confidence that the drug retains its strength, quality, and purity under appropriate storage conditions. In this paper we focus on liquid drug formulations and propose a Bayesian approach to estimate a drug product's shelf-life, where prior knowledge gained from the accelerated study conducted during the drug development stage is used to inform the long-term study. Classical and non-linear Arrhenius regression models are considered for the accelerated conditions, and two examples are given where posterior results from the accelerated study are used to construct priors for a long-term stability study.